About this episode

Jeff Jonas, M.D. discusses Tortugas Neuroscience's approach to CNS drug development and strategies for proving safety and efficacy.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jeff Jonas, M.D., CEO of Tortugas Neuroscience, talks about the company's April 2026 launch and how in-licensed development assets were chosen. Jeff explains his strategy of chasing fast proof of safety and efficacy in humans, not animals, and talks about what product differentiation looks like in brain disorders, from adjusting indication targets to conducting head-to-head trials. He al...

People in this episode

Host: Ben Comer

Guest: Jeff Jonas, M.D.

Topics covered

• CNS Drug Development
• Neuroscience
• Product Differentiation
• Clinical Trials
• Safety and Efficacy

Keywords

• CNS
• Drug Development
• Neuroscience
• Clinical Trials
• Safety
• Efficacy
• Brain Disorders

Mentioned in this episode

Organizations: Tortugas Neuroscience

More episodes of Business Of Biotech

• The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry · June 8, 2026 · 1h 24m
• Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane · May 25, 2026 · 55 min
• Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D. · May 18, 2026 · 51 min
• Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D. · May 11, 2026 · 54 min

Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.